First Human-AI Hybrid Brain Interface Approved for Consumer Use

WASHINGTON — The Food and Drug Administration approved NeuraLink Pro for consumer sale Friday, clearing the first direct human-AI neural interface for purchase without a prescription. The device, a coin-sized cortical patch applied via a 20-minute outpatient procedure, allows users to interface with AI systems through directed thought. It will retail for $2,400 and be available at participating electronics stores beginning next month.

The FDA's approval followed a 14-month review of clinical trial data covering 8,200 participants. The agency found the device safe and effective for its stated purpose — augmenting working memory and enabling hands-free AI interaction — with a side-effect profile it described as 'acceptable.' The most commonly reported side effect was vivid dreaming. The least commonly reported, affecting 0.3% of trial participants, was described in the clinical documentation as 'persistent sense of being observed.' Researchers noted this resolved within six weeks in all cases.

Consumer advocacy groups raised immediate concerns about data privacy. NeuraLink Pro's terms of service, which users must accept before activation, grant the manufacturer access to 'interaction metadata' — a category the company defines broadly and which its privacy policy describes across 34 pages of dense legal text. 'You are agreeing to share your thoughts,' said one advocate, 'with a company whose data retention policy runs to page 34.' The company said the data is used solely to improve the product.

Neurologists have been more measured. Several noted that the device's capabilities, while genuinely novel, are narrower than media coverage has suggested. 'It does not read your mind,' said Dr. Amara Osei of Johns Hopkins. 'It reads specific directed signals you consciously generate. That is a meaningful distinction.' She added that she had applied for one herself.

Pre-orders opened Friday afternoon and sold out within four hours. A second production run is expected in eight weeks. NeuraLink's CEO, in a post on the company's social platform, wrote: 'Today we crossed a threshold. There is no going back, and I mean that in the best possible way.' The post received 2.4 million likes before he deleted it and reposted it without the second sentence.